Promising candidates currently under investigation include the combination of dasatinib and quercetin (D+Q), selective (BCL-xL (B-cell lymphoma extra large) inhibitors (e.g., AZD0466), peptides designed to inhibit the FOXO4 (forkhead box O4)–p53 interaction, and PP2A (protein phosphatase 2A) activators [105,106,107,108]. The gene discussed is FOXO4; the disease is B-cell non-Hodgkin lymphoma.